Epigenomic iPSC Reprogramming Signatures
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for reprogramming somatic cells to a pluripotent state lack comprehensive understanding of epigenomic changes, particularly in DNA methylation patterns, leading to variability and aberrant reprogramming in induced pluripotent stem cells (iPSCs) compared to embryonic stem cells (ESCs).
Innovation Solution
The development of methods to identify and characterize non-CpG hypomethylated and CpG differentially methylated regions (DMRs) in iPSCs, allowing for the differentiation between fully and incompletely reprogrammed cells by comparing methylation patterns to those of ESCs, which helps in diagnosing reprogramming efficacy and propagation of altered methylation states.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If comprehensive epigenomic profiling is performed to understand DNA methylation changes during reprogramming, then measurement precision of epigenetic marks is improved, but device complexity and loss of time increase
Solution Approach 1:
The patent segments the complex epigenomic profiling task into distinct components: DNA extraction, bisulfite conversion, adapter ligation, and sequencing. Each step is optimized independently, with specific protocols for converting unmethylated cytosines to uracils while preserving methylated cytosines, enabling precise detection of DNA methylation patterns without overwhelming system complexity
Solution Approach 2:
The patent introduces bisulfite conversion as an intermediary chemical process that transforms unmethylated cytosines into uracils, creating a detectable difference between methylated and unmethylated cytosines. This intermediary step enables accurate measurement of epigenetic marks by converting epigenetic information into sequence variation that can be detected by standard sequencing technologies
2Reliability
If complete reversion of somatic epigenome to ESC-like state is required, then reliability of pluripotent state is improved, but loss of time and productivity decrease
Solution Approach 1:
The patent employs feedback mechanisms by using identified DMRs as diagnostic markers to assess reprogramming completeness. The methods detect whether specific genomic regions have achieved the expected hypomethylated or hypermethylated states characteristic of ESCs, providing real-time feedback on reprogramming progress and enabling identification of incompletely reprogrammed cells that can be sorted or discarded
Solution Approach 2:
The patent performs preliminary identification of key DMRs that serve as indicators of complete reprogramming before final cell differentiation. By establishing a profile of expected methylation changes at specific genomic loci during reprogramming, the method prepares reference data that enables rapid assessment of whether cells have achieved the desired ESC-like epigenetic state, streamlining quality control
3Measurement precision
If identification of non-CpG hypomethylated and CpG differentially methylated regions is implemented, then measurement precision of reprogramming status is improved, but difficulty of detecting and measuring increases
Solution Approach 1:
The patent applies local quality by focusing measurement efforts on specific differentially methylated regions (DMRs) rather than attempting to analyze the entire genome uniformly. The methods identify and prioritize particular genomic loci that show consistent methylation changes between ESCs and iPSCs, concentrating analytical resources on these informative regions to achieve high measurement precision without requiring exhaustive genome-wide analysis
Solution Approach 2:
The patent changes the measurement parameter from analyzing all cytosines uniformly to specifically targeting differentially methylated regions with altered methylation patterns. By shifting focus to regions where methylation status differs between cell types (non-CpG hypomethylated and CpG differentially methylated regions), the method simplifies detection while maintaining or improving measurement precision for reprogramming status
4Loss of information
If comprehensive base-resolution epigenomic profiling is performed across multiple cell lines, then loss of information about epigenetic variability is reduced, but loss of time and resource consumption increase
Solution Approach 1:
The patent applies partial action by performing comprehensive profiling on a representative subset of cell lines and conditions rather than every possible sample. The methods identify key DMRs and methylation patterns in selected ESC and iPSC lines, then use these findings to efficiently screen additional samples, retaining essential information about epigenetic variability while reducing overall time and resource requirements through strategic sampling
Data Source
AI summary
Provided herein are methods of characterizing the epigenetic signature of human induced pluripotent stem cells. The methods are useful in identifying human induced pluripotent stem cells (hiPSCs), diagnostic markers for incomplete hiPSCs reprogramming, and characterization of the efficacy of different reprogramming techniques.